RNAi Technology Market was valued at US$ 1,783.5 Mn in 2021 and is forecast to reach a value of US$ 3,506.5 Mn by 2028 at a CAGR of 10.1% between 2022 and 2028 | QIAGEN, Dicerna Pharmaceuticals Inc., Phio Pharmaceuticals Corp

The market for RNAi technology was valued at US$ 1,783.5 Mn in 2021 and is anticipated to grow at a CAGR of 10.1% from 2022 to 2028 to reach US$ 3,506.5 Mn. Due to the rising incidence of chronic diseases like cancer, diabetes, TB, and AIDS as well as the rising number of RNAi medicines or pharmaceuticals that have been approved, the global RNAi technology market is expanding rapidly. Additionally, increased attention on the development of RNAi therapeutics is anticipated to fuel market expansion. The global RNAi technology industry is predicted to increase, but issues including strict laws and regulations and the unstable, potentially immunogenic nature of RNA are expected to restrain it.

To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5281

Regional Insights

Geographical divisions of the worldwide RNAi technology market include North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.

Because of the rising prevalence of the target diseases and the rising need for sophisticated diagnostics and therapies, particularly in the United States, North America is anticipated to obtain the largest market share over the course of the projected period. For instance, there are several RNAi therapies being developed in the United States. After heart disease, cancer ranks as the second most common cause of mortality in the United States. The American Cancer Society predicts that there will be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the United States in 2022. The need has increased because to the rise in cancer prevalence.

The market for RNAi technology is anticipated to expand significantly in Asia Pacific as a result of the region’s rising cancer incidence and ageing population. For instance, a recent report by the Indian Council for Medical Research (ICMR) estimates that by 2025, there would be 29.8 million cancer patients in India, up from 26.7 million in 2021. Many pharmaceutical and biotech businesses have made large expenditures in the research and development of RNAi therapies. The global RNAi technology market is hence anticipated to grow more quickly in this area as a result.

Drivers

Over the course of the forecast period, it is anticipated that the prevalence of chronic illnesses like cardiovascular disease, cancer, diabetes, TB, AIDS, and more would increase across the world. Therapeutics based on RNA have the potential to treat a wide range of chronic illnesses as well as uncommon and hereditary abnormalities. According to the World Health Organization (WHO), chronic respiratory illnesses, cancer, and diabetes are the top causes of NCD (Non Communicable Disease) fatalities, each year accounting for 17.9 million deaths (2.0 million).

Inquire More Or Share Questions If Any Before The Purchase On This Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/5281

Over the forecast period, more RNAi medicines or therapeutics are anticipated to be approved, which is anticipated to boost market growth. For instance, because RNA-based therapies have the potential to treat a wide range of ailments, market participants are concentrating on creating new RNA-based therapeutics. Leqvio, a small interfering RNA (SiRNA) therapy for low-density lipoprotein that requires two doses each year after an initial dose and one at three months, was given FDA clearance in December 2021 by Novartis.

Market Opportunities

Players in the worldwide RNAi technology market can anticipate significant growth possibilities as a result of the COVID-19 (pandemic) outbreak. For example, COVID-19 therapies are being developed with success using RNAi. The two categories of RNAi and Ionis pharmaceuticals are investing heavily in RNAi technology and/or for RNAi therapeutic development, according to an article published in July 2020 (titled Prospects for RNAi therapy of COVID-19), as RNA based therapeutics have the potential to treat many chronic diseases as well as rare and genetic disorders. In consequence, this is anticipated to present significant growth prospects for market participants.

Market Trends

Long-term RNAi-based medicines have a bright future ahead of them, as does any clinical experience with them. Therapies or medicines based on RNA interference have the potential to treat a wide range of illnesses as well as uncommon and hereditary problems. As a result, pharmaceutical and biotech companies are spending a lot of money developing RNAi therapeutics, and this trend is anticipated to last throughout the projected period.

Due to supportive government efforts and policies, the availability of sizable research funds, and a sizable infrastructure for research and development, the research activities for RNA-based medicines are expanding throughout the world, but mainly in North America (R&D). Throughout the projection period, it is anticipated that this tendency would persist, fueling market expansion.

Market Restraints

The possible immunogenic immunogenicity of unstable RNA is anticipated to restrain the growth of the global RNAi technology market. For example, RNA often needs a delivery vehicle for effective transport to the targeted cells because it is intrinsically unstable, potentially immunogenic, and potentially immunogenic. Additionally, due to its immunogenicity and labile nature, mRNA is not suitable for clinical application in its current state.

The market for RNAi technology is anticipated to experience growing challenges due to strict rules and regulations. For instance, obtaining FDA (Food and Drug Administration) approval for a new drug has grown to be very difficult, and the FDA’s rate of drug approval has been declining recently. This is also anticipated to impede the development of the market.

Market Segmentation

Application and geography are divided into segments in the worldwide RNAi technology market study.

The global RNAi technology market is divided into Therapeutics and Drug Discovery and Development based on application. Due to the increased attention being paid to the development of RNAi therapeutics, the Therapeutics Segment is anticipated to lead the market for pain management devices during the course of the projected period. RNAi technology has demonstrated positive therapeutic outcomes for a variety of illnesses, particularly cancer. RNAi is a quick, cheap, and effective way to treat cancer.

Key Developments

Alnylam submitted a CTA Application in March 2019 for ALN-AGT, an investigational RNAi therapy for the management of hypertension in situations with significant unmet need.

The first RNA interference medication, Onpattro (patisiran) from Alnylam, received FDA approval in August 2018 to treat adult patients with the rare condition hereditary transthyretin-mediated amyloidosis (hATTR), which causes nerve damage.

Thermo Fisher Scientific purchased IntegenX, a company that offers cutting-edge fast DNA technology for human identification, in March 2018.

Key Companies Insights

The market for RNAi technology is very cutthroat. This can be attributable to the rising frequency of chronic diseases worldwide, which has led market participants to concentrate on introducing novel products.

Some of the major companies in the world market for RNAi technology include Sigma Aldrich, Thermo Fisher Scientific Inc., Ionis Pharmaceuticals Inc., Benitec Biopharma Ltd., Arcturus Therapeutics, Silence Therapeutics PLC, Phio Pharmaceuticals Corp., SBI Biotech Co. Ltd., Dicerna Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., and QIAGEN, are among the pharmaceutical companies that are involved.

Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/5281

Table of Contents:

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snapshot, By Application
     • Market Snapshot, By Geography
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Increasing approvals for RNAi therapeutics
     • Stringent rules and regulations
     • The outbreak of COVID-19 (pandemic)
   • Impact Analysis
   • Key Highlights
   • Regulatory Scenario
   • Product launch/Approvals
   • PEST Analysis
   • PORTER’s Analysis
   • Merger and Acquisition Scenario
4. Global RNAi Technology Market – Impact of Coronavirus (Covid-19) Pandemic
   • COVID-19 Epidemiology
   • Supply Side and Demand Side Analysis
   • Economic Impact
5. Global RNAi Technology Market, By Application, 2017-2028, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2028 (%)
     • Y-o-Y Growth Analysis, 2017 – 2028
     • Segment Trends
   • Drug Discovery and Development
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
   • Therapeutics
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

View Press Release: https://www.coherentmarketinsights.com/press-release/rnai-technology-market-4577